期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米诱导卵巢癌SKOV-3细胞凋亡的机制 被引量：1

下载PDF
导出
摘要 目的探讨硼替佐米诱导卵巢癌SKOV-3细胞凋亡的机制。方法采用MTT法检测硼替佐米对SKOV-3细胞的细胞生长抑制率,免疫组化法及Western印迹法检测bcl-2、bad蛋白表达的变化。结果硼替佐米明显抑制SKOV-3细胞的增殖,48 h后随着作用时间的延长和药物浓度的升高,抑制作用越来越明显,呈明显的时间-剂量依赖关系(P<0.05)。硼替佐米能够有效降低抗凋亡蛋白bcl-2的表达和增加促凋亡蛋白bad的表达。结论硼替佐米能够有效抑制SKOV-3细胞的增殖;可能通过减少bcl-2蛋白和增加bad蛋白的表达来诱导细胞凋亡。
作者 马宁 刘子玲 马克威 赵殿凤 张永峰
机构地区 吉林大学第一医院风湿科 吉林大学第一医院肿瘤中心 吉林大学第四医院肿瘤科
出处 《中国老年学杂志》 CAS CSCD 北大核心 2010年第2期222-224,共3页 Chinese Journal of Gerontology
基金 吉林省科技厅基金资助项目(20050412-3)
关键词 硼替佐米 凋亡 卵巢癌
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Lenz H. Clinical update:proteasome inhibitors in solid tumors[ J ]. Cancer Treat Rev,2003 ;29( 1 ) :41-8.
  • 2Cusack JC, Rong L, Houston M, et al. ECPT-I1 with proteasome inhibitor PS-341 :implications for systemic nuclear factor-KB inhibition [ J ]. Cancer Res,2001 ;61:3535-40.
  • 3Julian A. Development of the proteasome inhibitor PS-341 [J]. Oncologist,2002 ;7:9-16.
  • 4LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a routine model[ J]. Cancer Res,2002 ;62( 17 ) :4996-5000.
  • 5李明,缪泽鸿,丁健.蛋白酶体及其抑制剂的研究进展[J].中国药理学通报,2008,24(5):565-569. 被引量：9
  • 6Mortenson MM, Schlieman MG, Virudachalam S,et al. Reduction in bcl-2 levels by 26S proteasome inhibition with bortezomib is associated with in- duction of apoptosis in small cell lung cancer[J]. Lung cancer,2005 ;49 (2) :163-70.
  • 7Tanaka K, Iwamoto S, Gon G, et al. Expression of surviving and its rela- tionship to loss of apoptosis in breast carcinomas [J]. Clin Cancer Res, 2000 ; 6 : 127.
  • 8Kohler T, Schill C, De Ininger MW, et al. High bad and bax mRNA expression correlate-with negative outcome in acute myeloid leukemia (AML) [J]. Leukemia,2002 ; 16( 1 ) :22.

二级参考文献27

  • 1Raasi S, Wolf D H. Ubiquitin receptors and ERAD: A network of pathways to the proteasome [ J ]. Semin Cell Dev Biol, 2007,18 (6) :78 -91.
  • 2Fricke B, Heink S, Steffen J, et al. The proteasome maturation protein POMP facilitates major steps of 20S proteasome formation at the endoplasmic reticulum[ J]. EMBO Rep, 2007,8(12) :1170 - 5.
  • 3Meiners S, Ludwig A, Stangl V, et al. Proteasome inhibitors: Poisons and remedies [ J ]. Med Res Rev, 2008,28 (2) :309 - 27.
  • 4Marques A J, Glanemann C, Ramos P C, et al. The C-terminal extension of the beta 7 subunit and activator complexes stabilize nascent 20s proteasomes and promote their maturation [ J ]. J Biol Chem, 2007,282 (48) :34869 - 76.
  • 5Kim H T, Kim K P, Lledias F, et al. Certain pairs of ubiquitinconjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages [ J ]. J Biol Chem, 2007. 282 ( 24 ) : 17375 - 86.
  • 6Kwon Y T, Kashina A S, Varshavsky A. Alternative splicing resuits in differential expression, activity, and localization of the two forms of arginyl-tRNA-protein transferase, a component of the Nend rule pathway [ J ]. Mol Cell Biol, 1999.19 (1) : 182 -93.
  • 7Ludwig H, Khayat D, Giaccone G, et al. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies[ J]. Cancer, 2005. 104(9) : 1794 - 807.
  • 8lnoue J, Gohda J, Akiyama T, et al. NF-kappaB activation in development and progression of cancer [ J ]. Cancer Sci, 2007.98 (3) : 268 - 2674.
  • 9Adams J. The development of proteasome inhibitors as antieaneer drugs[J]. Cancer Cell, 2004.5(5) : 417 -21.
  • 10Sasaki M, Nie L, Maki C G. MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation[ J]. J Biol Chem, 2007. 282 (19) : 14626-34.

共引文献8

同被引文献9

  • 1Mortenson MM,Schlieman MG,Virudachalam S. Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer[J].Lung Cancer,2005,(02):163-170.doi:10.1016/j.lungcan.2005.01.006.
  • 2Mortenson MM,Schlieman MG,Virudachalam S. Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer[J].Lung Cancer,2005,(02):163-170.doi:10.1016/j.lungcan.2005.01.006.
  • 3Poveda Velasco A,Casado Herráez A,Cervantes Ruipérez A. Treatment guidelines in ovarian cancer[J].Clin Transl Oncol,2007,(05):308-316.
  • 4Pérez-Tomás R. Multidrug resistance:retrospect and prospects in anti-cancer drug treatment[J].Current Medicinal Chemistry,2006,(16):1859-1876.
  • 5Jemal A,Siegel R,Ward E. Cancer statistics,2008[J].CA-A Cancer Journal for Clinicians,2008,(02):71-96.
  • 6Ciechanover A. Intracellular protein degradation:from a vague idea,through the lysosome and the ubiquitin-proteasome system,and onto human diseases and drug targeting (Nobel lecture)[J].Angew Chem Int Ed Engl,2005,(37):5944-5967.
  • 7Adams J. Proteasome inhibitors as new anticancer drugs[J].Current Opinion in Oncology,2002,(06):628-634.doi:10.1097/00001622-200211000-00007.
  • 8Zhu H,Zhang L,Dong F. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341,Velcade) and other proteasome inhibitors[J].ONCOGENE,2005,(31):4993-4999.doi:10.1038/sj.onc.1208683.
  • 9廖爱军,杨威,付倍蓓,李迎春,张嵘,刘卓刚.不同浓度硼替佐米对K562/DNR细胞株NF-κB,IκB及P-gp表达的影响[J].第四军医大学学报,2009,30(15):1379-1382. 被引量：4

引证文献1

二级引证文献1

中国老年学杂志
2010年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部